Dr. Didier Mandelbrot
Dr. Mandelbrot is interested in novel methods for measuring renal function. He is working to establish a BIDMC Renal Function Clinic, where he will be performing direct measurements of GFR and other aspects of renal function. He has also collaborated with the nuclear medicine division to develop a novel method to accurately measure the relative function of native and transplanted kidneys in recipients of combined liver-kidney transplants.
As Medical Director of the Living Kidney Donor Program, another area of interest is in the evaluation and follow-up of living kidney donors. He has performed several national surveys to document current practices at U.S. transplant centers, and is analyzing the BIDMC database on living donors.
He is also performing studies of immunosuppressive regimens in renal transplantation, including (1) the role of IL-2 receptor antibodies in induction regimens, (2) the role of low-dose anti-thymocyte globulin for induction, (3) the effect of converting patients from calcineurin inhibitors to sirolimus, (4) outcomes using steroid free regimens in recipients of kidneys from cardiac death donors, and (5) the role of continued immunosuppression in patients with failed grafts who are back on dialysis.
He is also serving as the site principal investigator for multi-center trials of the novel calcineurin inhibitor ISA 247, the novel Jak kinase inhibitor CP-690,550 and the use of ramipril for proteinuria induced by sirolimus.